[{"address1": "Generaal De Wittelaan L11 A3", "city": "Mechelen", "zip": "2800", "country": "Belgium", "phone": "32 1 534 29 00", "fax": "32 1 534 29 01", "website": "https://www.glpg.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.\u00e0 r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.", "fullTimeEmployees": 683, "companyOfficers": [{"maxAge": 1, "name": "Dr. Paulus A. Stoffels M.D., Ph.D.", "age": 61, "title": "CEO, Chairman, Interim Head of R&D", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1404123, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thad  Huston", "age": 52, "title": "Executive VP, CFO & COO", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sofie  Van Gijsel", "title": "Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Valeria  Cnossen", "age": 49, "title": "Executive VP & General Counsel", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Marieke  Vermeersch", "title": "Head of Corporate Communication", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Annelies  Missotten", "age": 50, "title": "Executive VP & Chief Human Resources Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen Van Der Aar", "title": "Head of Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philippe  Alen M.B.A., Ph.D., Pharm.D.", "title": "Senior VP & Head of Business Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dirk  De Naeyer", "title": "Head of Development Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alice  Dietrich", "title": "Head of Medical Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 4, "compensationRisk": 10, "shareHolderRightsRisk": 4, "overallRisk": 7, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 26.2, "open": 26.2, "dayLow": 26.2, "dayHigh": 26.2, "regularMarketPreviousClose": 26.2, "regularMarketOpen": 26.2, "regularMarketDayLow": 26.2, "regularMarketDayHigh": 26.2, "beta": 0.094, "trailingPE": 46.320755, "volume": 190, "regularMarketVolume": 190, "averageVolume": 1293, "bid": 25.4, "ask": 31.55, "bidSize": 38800, "askSize": 29200, "marketCap": 1934466304, "fiftyTwoWeekLow": 22.6, "fiftyTwoWeekHigh": 37.25, "priceToSalesTrailing12Months": 7.40035, "fiftyDayAverage": 23.926, "twoHundredDayAverage": 29.99085, "currency": "USD", "enterpriseValue": -1801773952, "profitMargins": 1.0810701, "floatShares": 44543784, "sharesOutstanding": 65897100, "heldPercentInsiders": 0.25361001, "heldPercentInstitutions": 0.32161, "bookValue": 44.164, "priceToBook": 0.5558826, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 0.761, "netIncomeToCommon": 31500000, "trailingEps": 0.53, "enterpriseToRevenue": -6.893, "enterpriseToEbitda": 17.783, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "GLPGF", "underlyingSymbol": "GLPGF", "shortName": "GALAPAGOS NV", "longName": "Galapagos NV", "firstTradeDateEpochUtc": 1249306200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f582db48-6c62-3d98-a3ff-58ab7ef396b9", "gmtOffSetMilliseconds": -14400000, "currentPrice": 24.55, "recommendationKey": "none", "totalCash": 3430419968, "totalCashPerShare": 52.057, "ebitda": -101320000, "totalDebt": 10873000, "quickRatio": 9.682, "currentRatio": 10.048, "totalRevenue": 261402000, "debtToEquity": 0.374, "revenuePerShare": 3.967, "returnOnAssets": -0.01762, "returnOnEquity": 0.011469999, "freeCashflow": -292629504, "operatingCashflow": -374551008, "earningsGrowth": 0.748, "revenueGrowth": 0.297, "grossMargins": -0.13574, "ebitdaMargins": -0.38759997, "operatingMargins": -0.4903, "financialCurrency": "EUR", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]